TZIELD Shows Promise in Delaying Type 1 Diabetes Onset in Children and Young Adults

A two-week intravenous treatment helped delay the progression of type 1 diabetes in people ages 8–49 who had stage 2 disease. This is one step in a longer journey toward better ways to manage the condition's progression.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

TZIELD (teplizumab-mzwv) is given as an IV infusion over 14 days
The treatment delayed the onset of stage 3 type 1 diabetes in children and adults with stage 2 disease
The study included people ages 8–49
TZIELD delays progression but is not a cure for type 1 diabetes

What Is TZIELD and How Does It Work?

TZIELD (teplizumab-mzwv) is an intravenous treatment delivered over a 14-day period. It is designed for people with stage 2 type 1 diabetes who have not yet developed stage 3 disease. Stage 2 refers to the phase when the immune system is actively attacking insulin-producing cells but blood sugar levels remain normal. Stage 3 is when blood sugar control becomes impaired and symptoms typically appear.

What the Research Shows

In a study involving children and adults ages 8–49 with stage 2 type 1 diabetes, TZIELD delayed the progression to stage 3 disease. This means that people who received the treatment took longer to develop the symptoms and blood sugar changes that define clinical type 1 diabetes. However, the treatment does not prevent the disease entirely or cure it—it extends the time before symptoms emerge.

Who May Be Eligible

TZIELD was studied in people between ages 8 and 49 who had already been identified as having stage 2 type 1 diabetes. This typically means they have been diagnosed through screening and testing, not because they have obvious symptoms. If you or a family member think you may be at risk for type 1 diabetes, talk with your healthcare provider about whether screening or further evaluation makes sense for your situation.

What This Means for the Future

Delaying the onset of type 1 diabetes could give people more time before they need to manage blood sugar with insulin and other medications. It may also reduce the intensity of initial symptoms. While this is a meaningful step forward, it is important to remember that TZIELD is a delay, not a prevention or cure. Ongoing research continues to explore ways to better manage and eventually prevent type 1 diabetes altogether.

Evidence label

Origin: Vera Health (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.